SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 212 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $3,992,000 | +21.6% | 158,677 | +0.8% | 0.02% | -45.5% |
| Q3 2020 | $3,282,000 | +1.1% | 157,477 | +15.2% | 0.04% | +76.0% |
| Q2 2020 | $3,247,000 | -99.9% | 136,735 | -2.7% | 0.02% | 0.0% |
| Q1 2020 | $2,528,000,000 | -30.9% | 140,535 | -8.8% | 0.02% | +4.2% |
| Q4 2019 | $3,656,000,000 | +39039.3% | 154,135 | -54.7% | 0.02% | -63.1% |
| Q3 2019 | $9,341,000 | -33.8% | 339,910 | -20.2% | 0.06% | -33.0% |
| Q2 2019 | $14,103,000 | -28.4% | 426,210 | -24.2% | 0.10% | -30.2% |
| Q1 2019 | $19,705,000 | -4.7% | 562,360 | -9.7% | 0.14% | -20.6% |
| Q4 2018 | $20,678,000 | +5.5% | 622,460 | +59.9% | 0.18% | +24.1% |
| Q3 2018 | $19,603,000 | -25.1% | 389,335 | -11.0% | 0.14% | -31.6% |
| Q2 2018 | $26,184,000 | +237.4% | 437,500 | +158.2% | 0.21% | +243.3% |
| Q1 2018 | $7,761,000 | – | 169,475 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $17,478,000 | 3.94% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,124,405 | $36,341,000 | 3.91% |
| ARMISTICE CAPITAL, LLC | 3,100,000 | $100,192,000 | 1.94% |
| S&T BANK/PA | 316,326 | $10,224,000 | 1.54% |
| Bruce & Co., Inc. | 222,105 | $7,178,000 | 1.47% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 379,875 | $12,278,000 | 1.36% |
| RICE HALL JAMES & ASSOCIATES, LLC | 854,949 | $27,632,000 | 1.10% |
| Soleus Capital Management, L.P. | 251,000 | $8,112,000 | 1.05% |
| Parkman Healthcare Partners LLC | 108,954 | $3,521,000 | 1.03% |
| Aristotle Capital Boston, LLC | 1,258,067 | $40,661,000 | 1.03% |